How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing Full Text available with Trip Pro

and protein expression, in a tissue- and transporter-dependent manner. Depo-Provera-synchronized mice were dosed vaginally or intraperitoneally with (3)H-TFV, with or without MK571 co-administration, to delineate the function of cervicovaginal Mrp4. Co-administration of MK571 significantly increased the concentration of vaginally-administered TFV in endocervix and vagina. MK571 increased the concentration of intraperitoneally-administered TFV in the cervicovaginal lavage and vagina by several fold

2016 Biochemical pharmacology

202. Trends in contraceptive practices among women in reproductive age at a health facility in Ghana: 2011–2013 Full Text available with Trip Pro

of a health facility for a three-year period from 2011 to 2013. Graphs and tables were used to present the trends in the use of various contraceptive methods for the study period.Depot Medroxyprogesterone Acetate (Depo-Provera) was the most accepted contraceptive method as well as the most protective method against unwanted pregnancies for the three-year period. However, male condom, estradiol valerate/norethindrone enanthate (Norigynon) and pills were the lowest among all the contraceptives used by women

2016 Contraception and Reproductive Medicine

203. Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the study. (NOTE: The subject must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study). Exclusion Criteria: Subjects who received antibiotics within the last 14 days Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection

2016 Clinical Trials

204. Restylane Silk Acne Scar Efficacy Evaluation Study

of age. Willing to refrain from undergoing any procedures to repair or augment any acne scar in the treatment area during the study. Female subjects with a negative pregnancy test confirmed at screening and on an acceptable form of birth control. Acceptable forms of birth control on this study include oral or injectable contraceptive, contraceptive patches, Depo-Provera, NuvaRing, Implanon, double barrier methods, IUD, same sex partner, or abstinence. Males will be required to use an acceptable

2016 Clinical Trials

205. A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

injections, combined pill, progestin-only pill, hormone-releasing transdermal patch or vaginal ring, and depot medroxyprogesterone acetate injection (Depo-Provera). Have one male sex partner who has had a vasectomy >/=3 months prior. Male partner with barrier protection plus the use of vaginal spermicide. Practice abstinence defined as refraining from heterosexual intercourse from 30 days before first vaccination until at least 60 days after last ZPIV vaccination. Female subjects must agree to not donate

2016 Clinical Trials

206. Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

contraceptives, contraceptive injections, combined pill, progestin-only pill, hormone-releasing transdermal patch or vaginal ring, and depot medroxyprogesterone acetate injection (Depo-Provera), OR Male sex partners must have had a vasectomy > /= 3 months prior to first vaccination, OR Practice abstinence defined as refraining from heterosexual intercourse from 30 days before first vaccination until the end of the study. Female subjects must agree to not donate eggs (ova, oocytes) from the start of screening

2016 Clinical Trials

207. Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

of treatment with open label RHB-104 (Refer to Appendix 13) White blood cell count ≥ 3.5x109 at screening (RHB-104-01 Visit Week 26 visit or Optional Screening visit) Subject agrees to use the following effective contraceptive methods diaphragm, cervical cap, contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository IUD (intrauterine device) /IUS (intrauterine system) progestogen injection (Depo-Provera®) throughout the study and for at least 6 weeks after last study drug administration

2016 Clinical Trials

208. Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD intrauterine device/IUS levonogestrel Intrauterine system, Depo-Provera(tm) injections, oral contraceptive, and Evra Patch(tm) or Nuvaring(tm). WOCBP must agree to use effective method of birth control, as defined above, from enrolment, throughout the study duration and within

2016 Clinical Trials

209. Vitamin D Supplementation in Women With DCIS and/or LCIS

-string) Exclusion Criteria: Patient desires not to participate in the study Inability to give consent Current use of hormone-containing forms of birth control such as implants (i.e. Norplants, or injectables (i.e. depo-provera) Currently lactating Patients with history of renal or hepatic insufficiency Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication History of granulomatous disease such as tuberculosis or sarcoidosis

2016 Clinical Trials

210. Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF

. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives

2016 Clinical Trials

211. Making Healthy Decisions

intervention ] Number of partners with whom had vaginal, oral, or anal sex without using condoms or insertive condoms Number of sexual partners without using condoms [ Time Frame: 9 months post intervention ] Number of partners with whom had vaginal, oral, or anal sex without using condoms or insertive condoms Birth control use [ Time Frame: 3 months post intervention ] Use and consistency of use of 14 birth control methods (birth control pills, patch, Depo Provera, ring, IUD, implant, condoms, female (...) condoms, diaphragm, cervical cap, sponge, spermicide, "safe time of month," "pull out"), and emergency contraception Birth control use [ Time Frame: 9 months post intervention ] Use and consistency of use of 14 birth control methods (birth control pills, patch, Depo Provera, ring, IUD, implant, condoms, female condoms, diaphragm, cervical cap, sponge, spermicide, "safe time of month," "pull out"), and emergency contraception Nutrition knowledge [ Time Frame: 3 months post intervention ] Count

2016 Clinical Trials

212. A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

with demonstrable ischemia Addition or change in dosing of hormonal contraception medications (OCP, IUD, Depo-Provera) in the past 4 weeks. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study or would prevent completion of the study

2016 Clinical Trials

213. The Monitoring Study

, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during the study Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days), use of marijuana within 1 month of enrollment, or other substance abuse (use within the last 6 months of controlled

2016 Clinical Trials

214. Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

at the time of screening visit. Complement C4 and C1 inhibitor panel within normal reference ranges. If a woman is of child-bearing potential, she must agree to a reliable form of birth control including: abstinence, oral contraceptives (birth control pills), Depo-provera, an IUD (intrauterine device), or double-barrier contraception (partner using condom and subject using diaphragm). Exclusion Criteria: Unable to give informed written consent, unable to adhere to the outlined visit schedule or unable

2016 Clinical Trials

215. Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstru

to the Screening Visit) Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent) Barrier methods (e.g., condoms with spermicide) Intrauterine device (i.e., IUD) Vasectomy of male partner Non-heterosexual life style Willing and able to provide written informed consent Exclusion Criteria: Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the patients at risk or which

2016 Clinical Trials

216. Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary

) Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent) Barrier methods (e.g., condoms with spermicide) Intrauterine device (i.e., IUD) Vasectomy of male partner Non-heterosexual life style Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular

2016 Clinical Trials

217. Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF

implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used

2016 Clinical Trials

218. Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

of investigational product. Woman who is of childbearing potential (ie, neither surgically sterile nor postmenopausal) and does not agree to use adequate contraception (eg, true abstinence, sterilization, birth control pills, Depo-Provera® [medroxyprogesterone] injections, or contraceptive implants) while on study and for 6 months after the last dose of investigational product. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2016 Clinical Trials

219. ZIKA Vaccine in Naive Subjects

ring, and depot medroxyprogesterone acetate injection (Depo-Provera), OR Male sex partners must have had a vasectomy >/=3 months prior to first vaccination, OR Practice abstinence defined as refraining from heterosexual intercourse from 30 days before first vaccination until at least 60 days after 2nd vaccination 10. Female subjects must agree to not donate eggs (ova, oocytes) from the start of screening period until at least 60 days after receiving the last vaccination 11. Subjects must provide

2016 Clinical Trials

220. Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies

procedures Female patients of childbearing potential must have a negative pregnancy test within 24 hours of dosing Women of childbearing potential and men who are able to father a child must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 12 months following administration of the study drug Patients with Multiple Myeloma At least 2 prior regimens

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>